A number of other analysts have also commented on CRSP. Chardan Capital reiterated a buy rating and set a $72.50 price target on shares of Crispr Therapeutics in a report on Monday, November 18th. Roth Capital lifted their price target on Crispr Therapeutics from $65.00 to $100.00 in a report on Tuesday, November 19th. TheStreet raised Crispr Therapeutics from a d rating to a c rating in a research report on Monday, October 28th. ValuEngine raised Crispr Therapeutics from a sell rating to a hold rating in a research report on Friday, November 1st. Finally, Oppenheimer raised their target price on Crispr Therapeutics from $65.00 to $80.00 and gave the stock an outperform rating in a research report on Monday, November 25th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and fourteen have assigned a buy rating to the company. The company currently has an average rating of Buy and an average target price of $69.54.
Shares of Crispr Therapeutics stock opened at $66.33 on Friday. The business’s fifty day simple moving average is $60.48 and its 200 day simple moving average is $48.87. The firm has a market capitalization of $3.61 billion, a P/E ratio of -19.28 and a beta of 3.30. Crispr Therapeutics has a 12 month low of $22.22 and a 12 month high of $74.00. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06.
Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Monday, October 28th. The company reported $2.40 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.95) by $3.35. The business had revenue of $211.93 million for the quarter, compared to analyst estimates of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. Analysts predict that Crispr Therapeutics will post 0.65 EPS for the current fiscal year.
In other Crispr Therapeutics news, Director Pablo J. Cagnoni sold 7,500 shares of the firm’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $62.00, for a total value of $465,000.00. Following the completion of the sale, the director now directly owns 7,500 shares of the company’s stock, valued at $465,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, President Rodger Novak sold 33,618 shares of Crispr Therapeutics stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the transaction, the president now owns 33,618 shares of the company’s stock, valued at $2,353,260. The disclosure for this sale can be found here. Insiders sold 56,118 shares of company stock valued at $3,620,760 over the last three months. Company insiders own 21.40% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in CRSP. NEXT Financial Group Inc grew its position in shares of Crispr Therapeutics by 915.0% in the third quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock valued at $25,000 after purchasing an additional 549 shares in the last quarter. Benjamin Edwards Inc. grew its position in shares of Crispr Therapeutics by 96.4% in the second quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock valued at $26,000 after purchasing an additional 268 shares in the last quarter. Coastal Investment Advisors Inc. purchased a new position in shares of Crispr Therapeutics in the third quarter valued at $26,000. US Bancorp DE grew its position in shares of Crispr Therapeutics by 553.7% in the second quarter. US Bancorp DE now owns 621 shares of the company’s stock valued at $29,000 after purchasing an additional 526 shares in the last quarter. Finally, BSW Wealth Partners purchased a new position in shares of Crispr Therapeutics in the second quarter valued at $39,000. Institutional investors own 49.82% of the company’s stock.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Story: What is the NASDAQ Stock Market?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.